NeoGenomics, Inc. (NEO)
Upgrades & Downgrades
Latest NEO news
NeoGenomics, Inc (NEO) Q2 2023 Earnings Call Transcript
8 August 2023
NeoGenomics, Inc (NASDAQ:NEO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations Chris Smith - Chief Executive Officer...
NeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
8 August 2023
Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Stree...
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
18 July 2023
FT. MYERS, FL / ACCESSWIRE / July 18, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that it will report its secon...
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
1 June 2023
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
NeoGenomics: What Lies Ahead
18 May 2023
Today, we take our first look at NeoGenomics, Inc., a company focused on oncology testing. NeoGenomics has strung together a series of strong quarterly results that has helped the shares double so far...
3 Best Breakout Stocks to Invest in for Superlative Returns
16 May 2023
First Watch Restaurant Group (FWRG), NeoGenomics (NEO), and Universal Stainless & Alloy Products (USAP) have been selected as the breakout stocks for today.
NeoGenomics, Inc. (NEO) Q1 2023 Earnings Call Transcript
8 May 2023
NeoGenomics, Inc. (NASDAQ:NEO ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - President of ...
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
8 May 2023
NeoGenomics (NEO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.20 per share a year ago.
3 Top Stocks Likely to Exceed Estimates This Earnings Season
28 April 2023
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Portillo's Inc. (PTLO), NeoGenomics (NEO) and Wingstop (WING).